Among the excluded patients with RA, anti-TNF-α therapy was discontinued for the following reasons: lack of response (five patients), loss of response (three patients), therapy intolerance (three patients), undergoing surgical procedures (four patients), and withdrawal of consent to participation in therapy (four patients). The gene discussed is TNF; the disease is rheumatoid arthritis.